HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Philip E Castle Selected Research

Uterine Cervical Dysplasia

1/2022Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management.
10/2020A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus-positive and -Negative Cervical Precancers.
11/2018Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report.
1/2018Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years.
6/2017Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era.
7/2015The Influence of Human Papillomavirus Genotypes on Visual Screening and Diagnosis of Cervical Precancer and Cancer.
1/2015Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.
12/2014Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.
6/2014Lower cost strategies for triage of human papillomavirus DNA-positive women.
4/2013Comparative risk of high-grade histopathology diagnosis after a CIN 1 finding in endocervical curettage versus cervical biopsy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Philip E Castle Research Topics

Disease

49Neoplasms (Cancer)
01/2022 - 09/2002
46Uterine Cervical Neoplasms (Cancer of the Cervix)
01/2021 - 09/2002
27Uterine Cervical Dysplasia
01/2022 - 09/2002
20Papillomavirus Infections
01/2020 - 01/2002
16Infections
01/2020 - 01/2002
13Atypical Squamous Cells of the Cervix
01/2022 - 01/2002
10Squamous Intraepithelial Lesions
10/2020 - 08/2004
4Anus Neoplasms (Anal Cancer)
10/2022 - 11/2012
3Carcinogenesis
09/2017 - 06/2008
3Inflammation (Inflammations)
07/2004 - 01/2002
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022 - 01/2015
2Vaginal Neoplasms (Cancer, Vaginal)
04/2016 - 01/2016
2Coinfection
02/2009 - 07/2004
2Carcinoma (Carcinomatosis)
10/2003 - 11/2002
2Sexually Transmitted Diseases (Sexually Transmitted Disease)
07/2003 - 07/2002
1Colorectal Neoplasms (Colorectal Cancer)
11/2019
1Disease Progression
11/2018
1Necrosis
07/2017
1Adenocarcinoma in Situ
04/2013
1Endometrial Neoplasms (Endometrial Cancer)
02/2010
1Cough
10/2007
1Reproductive Tract Infections
01/2003
1Tetanus
11/2002
1Human Influenza (Influenza)
11/2002
1Herpes Zoster
04/2002

Drug/Important Bio-Agent (IBA)

44DNA (Deoxyribonucleic Acid)IBA
01/2020 - 09/2002
18Biomarkers (Surrogate Marker)IBA
10/2022 - 11/2005
13VaccinesIBA
01/2022 - 07/2003
11Papillomavirus Vaccines (HPV Vaccines)IBA
01/2022 - 08/2009
6AntibodiesIBA
11/2017 - 03/2002
5Coloring Agents (Dyes)IBA
10/2022 - 12/2014
5Oral ContraceptivesIBA
02/2010 - 01/2002
4Acetic Acid (Vinegar)FDA LinkGeneric
03/2016 - 10/2007
3Messenger RNA (mRNA)IBA
09/2015 - 05/2007
3Complement System Proteins (Complement)IBA
03/2013 - 10/2003
2P-2 (P 2)IBA
12/2016 - 04/2013
2Diethylstilbestrol (Stilbestrol)FDA Link
04/2016 - 01/2016
2RNA (Ribonucleic Acid)IBA
09/2015 - 01/2013
2Oncogene Proteins (Oncogene Protein)IBA
09/2013 - 12/2010
2ParaffinIBA
04/2009 - 11/2007
2SmokeIBA
06/2008 - 11/2007
2Biological ProductsIBA
06/2007 - 11/2002
2CI 22IBA
10/2006 - 07/2005
2Contraceptive Agents (Contraceptives)IBA
12/2005 - 06/2005
2AntigensIBA
07/2003 - 11/2002
2Peptides (Polypeptides)IBA
07/2003 - 11/2002
2GoldIBA
11/2002 - 04/2002
2Glycoproteins (Glycoprotein)IBA
07/2002 - 04/2002
1Biological FactorsIBA
01/2022
1ORALIT (ORS)IBA
01/2020
1Hemoglobins (Hemoglobin)IBA
11/2019
1Proflavine (Proflavin)IBA
11/2018
1Amino AcidsFDA Link
09/2017
1hydrogen sulfite (bisulfite)IBA
02/2015
11,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA
01/2014
1Aligeron (AS 2)IBA
07/2012
1CarcinogensIBA
01/2012
1Selective Estrogen Receptor Modulators (SERM)IBA
02/2011
1polycyclic aromatic hydrocarbons-DNA adductIBA
11/2007
1Carbon DioxideIBA
10/2007
1GasesIBA
10/2007
1Therapeutic UsesIBA
10/2007
1Nitrous Oxide (Laughing Gas)IBA
10/2007
1N 30IBA
11/2005
1Telomerase (Telomerase Reverse Transcriptase)IBA
10/2003
1telomerase RNA (bTR)IBA
10/2003
1Capsid Proteins (Capsid Protein)IBA
07/2003
1Neutralizing AntibodiesIBA
07/2003
1Ligases (Synthetase)IBA
07/2003
1ImmunosorbentsIBA
07/2003
1EnzymesIBA
07/2003
1HTLV-I AntibodiesIBA
07/2003
1AntioxidantsIBA
01/2003
1PhytohemagglutininsIBA
11/2002
1DNA-Directed DNA Polymerase (Polymerases, DNA)IBA
11/2002
1MitogensIBA
11/2002
1Indicators and Reagents (Reagents)IBA
10/2002
1Heme (Haem)IBA
01/2002
1Interleukin-10 (Interleukin 10)IBA
01/2002
1Interleukin-12 (IL 12)IBA
01/2002

Therapy/Procedure

4Secondary Prevention
01/2019 - 01/2017
4Hysterectomy
04/2016 - 06/2005
3Cryotherapy (Therapy, Cold)
07/2017 - 10/2007
2Curettage
04/2013 - 11/2010
1Palliative Care (Palliative Therapy)
01/2019
1Conservative Treatment
01/2018
1Aftercare (After-Treatment)
04/2013
1Therapeutics
02/2013
1Ambulatory Care (Outpatient Care)
05/2011
1Injections
12/2005